Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2015
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 08 Dec 2015 New trial record